“WE ARE NOT POWERLESS, AND THROUGH OUR VIDEOS, WRITINGS, AND PHOTOGRAPHS WE WILL EXPOSE THE ABUSES AND TYRANNY JUST AS THE VIDEO WAS RECORDED BY THE CELL PHONE CAMERA OF YOUNG DARNELLA FRAZIER, BORE WITNESS TO THE MURDER OF GEORGE FLOYD THE BLOG youarewithinthenorms.com BARES WITNESS AND BOTH ALLOWS THE SYSTEM TO BE HELD ACCOUNTABLE”
REPORTED BY
NORMAN J CLEMENT RPH., D.D.S., NORMAN L.CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., IN THE SPIRIT OF REV. C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., N THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGWORTH, LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., M.B.A., BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., IN THE SPIRIT OF RICHARD KAUL, MD., N THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., M.B.A., ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
HERSH DINESH PATEL, MD, ADMITTED TO CRIMINAL WRONGDOING DURING CROSS-EXAMINATION AS A GOVERNMENT WITNESS IN THE DETROIT-5 TRIAL
“WE ARE HEALTHCARE PROVIDERS, NOT STREET DRUG DEALERS “
HERSH PATEL CROSSED BY DEFENSE ATTY LAURENCE MARGOLIS
Dr. Hersh Dinesh Patel, admitted in District Judge Stephen J. Murphy, III Court today and yesterday (6/6/2022 and 6/7/2022) in UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION in the criminal trial Crim. No. 2:18-cr-20800 that he prescribed unnecessary controlled substance medications to patients and that he intentionally and knowingly performed unnecessary interventional procedures upon patients without medical necessity. I will be forwarding this information to the Delaware Medical License Board.
June 6, 2022
Remmer v. United States protects the fairness of the legal system
NEW DATA ON OPIOID REDUCTIONS
| Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network
Richard Lawhern PHD, writes:
“This June 13, 2022 paper from Stefan G. Kertesz, MD, and Allyson L. Varley, Ph.D. is remarkable for multiple reasons. The paper reviews evidence recently published by others, that involuntary opioid dose restrictions and tapers not only do NOT promote safety for chronic pain patients but are arguably never justified without patient participation and careful monitoring to ensure that the patient is properly managed if tapering fails to produce a useful result. “
What I find perhaps most remarkable about this paper is that the Journal of the AMA published it at all. At least in my reading, JAMA has pursued a persistently anti-opioid editorial policy, despite the public positions of the AMA Board and CEO to the effect that the 2016 CDC guidelines on the prescription of opioids have arbitrarily and needlessly harmed many patients and their doctors.
Thus, I must regard the publication of this paper by JAMA to progress in changing the public conversation on these issues.
Feel free to share. This note will also be posted to multiple social media platforms.
DISCLAIMER
NOTE: RICHARD LAWHERN PH.D. IS NOT A PART OF NOR A PARTICIPANT IN THE COMPLAINT AGAINST PHYSICIAN HERSH PATEL, MD. LAWHERN’S WORK APPEARS IN THIS ARTICLE AS IT IS TIMELY AND HIGHLIGHTS MEDICAL SCIENTIFIC FACTS OVER PROSECUTORIAL COERCION
New Data on Opioid Dose Reduction—Implications for Patient Safety
From the paper:
“Reductions and stoppages in these patients’ prescription regimens are likely to reflect varied motivations and understandings among physicians and other professionals who care for them. Some may reduce doses on the belief that such reductions confer safety and well-being, a perspective reinforced by studies showing that voluntary tapers are achievable or even salutary for some patients.
However, it is likely that many clinicians are reacting to a fraught public discourse and to external pressures, including measures that rate the quality of their work.
According to a metric issued by the National Committee for Quality Assurance and adopted by most payers, patients taking a daily dose greater than the equivalent of 90 mg of morphine are considered to be receiving poor care, regardless of their prior dose history.2
Such measures do incentivize either reduction or termination of the care relationship. Unsurprisingly, dose reductions and stoppage have become more common in recent years.3“
And later in the paper:
“How should clinicians and health systems respond today, in light of these evolving, cautionary findings on opioid dose reduction?
Our view is that opioid dose reduction is likely to offer benefits for some while harming others. The harms may include worsening pain, distress, or death. Given this uncertain balance of harm and benefit, it would be wise for health systems to stop promoting this change in care.
A policy of tapering all patients to doses lower than a specified threshold cannot be supported by the available evidence. Quality metrics that incentivize these policies, such as the High Dose Opioid criterion promulgated by the National Committee for Quality Assurance,2 are overdue for retirement.
Indeed, experts who assisted the Centers for Disease Control and Prevention in developing its 2016 guideline urged that it not be adopted in the first place.16“
Richard A “Red” Lawhern PhD
Patient Advocate
Twitter: @Lawhern1
Facebook: https://www.facebook.com/red.lawhern
My Publications: http://www.face-facts.org/Lawhern
Personal Website: http://www.lawhern.org
FOR NOW, YOU ARE WITHIN
THE NORMS
OR SEND
$150 DOLLARS TO CASH APP:$docnorm
So, Donate to the “Pharmacist For Healthcare Legal Defense Fund,”
reference:
